← back to search

Lisa Baumann Kreuziger

Medical College of Wisconsin · US
Area of research
Internal Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Heparin-Induced Thrombocytopenia and Thrombosis, and COVID-19 Clinical Research Studies.
h-index
33
citations
4,309
works
171
NIH funding
primary concept
Medicine
email

Recent publications

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
New England Journal of Medicine 2026cited by 7position: middledoi
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned
Annals of Internal Medicine 2024cited by 43position: middledoi
Executive Summary: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE (PEACE) Consensus Conference*
Pediatric Critical Care Medicine 2024cited by 41position: middledoi
Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications
Seminars in Thrombosis and Hemostasis 2024cited by 16position: middledoi
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
The Lancet Diabetes & Endocrinology 2024cited by 12position: middledoi
Recommendations on Monitoring and Replacement of Antithrombin, Fibrinogen, and Von Willebrand Factor in Pediatric Patients on Extracorporeal Membrane Oxygenation: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference
Pediatric Critical Care Medicine 2024cited by 11position: middledoi
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Blood Advances 2024cited by 4position: middledoi
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Blood Advances 2023cited by 226position: middledoi
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer
JAMA 2023cited by 136position: middledoi
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
JAMA 2023cited by 97position: middledoi
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization
Annals of Internal Medicine 2023cited by 36position: middledoi
Associations between <scp>ABO</scp> non‐identical platelet transfusions and patient <scp>outcomes—A</scp> multicenter retrospective analysis
Transfusion 2023cited by 18position: middledoi
Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19
JAMA Network Open 2023cited by 17position: middledoi
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial
Circulation 2023cited by 16position: middledoi
DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network
Journal of Thrombosis and Thrombolysis 2023cited by 14position: middledoi
Race, rituximab, and relapse in TTP
Blood 2022cited by 37position: middledoi
Antithrombotic Therapy for VTE Disease
CHEST Journal 2021cited by 938position: middledoi
Executive Summary
CHEST Journal 2021cited by 389position: middledoi
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
BMJ 2021cited by 371position: middledoi
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
Blood Advances 2021cited by 49position: middledoi
Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy
Journal of Thrombosis and Haemostasis 2021cited by 40position: middledoi
Thrombo‐inflammatory biomarkers and D‐dimer in a biracial cohort study
Research and Practice in Thrombosis and Haemostasis 2021cited by 9position: middledoi
Antithrombotic therapy for left ventricular assist devices in adults: a systematic review
Journal of Thrombosis and Haemostasis 2015cited by 73position: firstdoi
A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis
Journal of Vascular Surgery Venous and Lymphatic Disorders 2015cited by 37position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Scott C. Woller · New York University3 papers (2021–2023)Andrew J. Knighton · Intermountain Healthcare2 papers (2021–2021)Philip S. Wells · University of Ottawa2 papers (2021–2021)Janine Vintch · UCLA Medical Center2 papers (2021–2021) · 2 papers (2021–2021)Clive Kearon · McMaster University2 papers (2021–2021)Jeffrey I. Zwicker · Amsterdam University Medical Centers2 papers (2021–2021)Henri Bounameaux · Assistance Publique – Hôpitaux de Paris2 papers (2021–2021)Kevin C. Doerschug · University of Iowa2 papers (2021–2021)Mary Cushman · Kidney Research UK2 papers (2021–2023)Menno V. Huisman · St. Antonius Ziekenhuis2 papers (2021–2021)Tzu‐Fei Wang · The Ohio State University2 papers (2021–2021)Geert‐Jan Geersing · Utrecht University2 papers (2021–2021)Kristen M. Sanfilippo · Brown University2 papers (2021–2023)Scott M. Stevens · Intermountain Healthcare2 papers (2021–2021)Susan Murin · University of California, Davis2 papers (2021–2021)Christopher S. King · Virginia Commonwealth University2 papers (2021–2021) · 2 papers (2021–2021)Pooja Khatri · Yale University1 papers (2023–2023)Andrei Kindzelski · National Heart Lung and Blood Institute1 papers (2023–2023)